Cargando…
Breaking down the RECIST 1.1 double read variability in lung trials: What do baseline assessments tell us?
BACKGROUND: In clinical trials with imaging, Blinded Independent Central Review (BICR) with double reads ensures data blinding and reduces bias in drug evaluations. As double reads can cause discrepancies, evaluations require close monitoring which substantially increases clinical trial costs. We so...
Autores principales: | Iannessi, Antoine, Beaumont, Hubert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060958/ https://www.ncbi.nlm.nih.gov/pubmed/37007064 http://dx.doi.org/10.3389/fonc.2023.988784 |
Ejemplares similares
-
RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
por: Iannessi, Antoine, et al.
Publicado: (2021) -
Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
por: Beaumont, Hubert, et al.
Publicado: (2023) -
Discrepancies of assessments in a RECIST 1.1 phase II clinical trial – association between adjudication rate and variability in images and tumors selection
por: Beaumont, Hubert, et al.
Publicado: (2018) -
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022) -
Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)